Poolbeg Pharma plc – Notice of Allowance for Significant POLB 001 Patent in United States

Notice of Allowance for Immunomodulator II further strengthens robust intellectual property portfolio

20 March 2024  Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has received a Notice of Allowance from the US Patent Office in relation to its Immunomodulator II patent application. A Notice of Allowance is a precursor to the expected formal grant of a patent in due course.

Read more…